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RESUMO 
Introdução e objetivo: A resposta inflamatória está envolvida em muitas das 
complicações observadas em pacientes com anemia falciforme (AF). O objetivo 
deste trabalho foi avaliar as concentrações séricas de duas citocinas anti-
inflamatórias recentemente descritas, a IL-27 e IL-37, e de algumas citocinas 
inflamatórias em pacientes brasileiros com AF em tratamento com hidroxiureia 
(HU) e comparar com pacientes não tratados e indivíduos controle. Além disso, 
procuramos demostrar o efeito da IL-27, IL-37 e heme in vitro na secreção de IL-
8 por neutrófilos e monócitos humanos. 
Métodos: Foi realizado um estudo transversal com 82 pacientes com AF (35 sem 
tratamento com HU e 47 em tratamento com HU) com a doença estável e 49 
indivíduos controle. Os dados clínicos foram obtidos a partir dos prontuários 
médicos e por meio de entrevista. As concentrações séricas de IL-27, IL-37, 
TGF-β, TNF-α, IL-1β, IL-6 e IL-8 foram determinadas por ELISA. Neutrófilos e 
monócitos foram isolados de indivíduos saudáveis e cultivados separadamente 
com ou sem citocinas (IL-27 e IL-37) e heme. As citocinas pró-inflamatórias no 
sobrenadante de cultura foram quantificadas por ELISA. 
Resultados: As concentrações séricas de IL-27, IL-37, IL-1β, IL-6 e IL-8 em 
pacientes tratados com HU foram significativamente maiores em comparação a 
controles HbAA. Não foi observada diferença entre os níveis séricos de citocinas 
pró e anti-inflamatórias, exceto IL-8, em pacientes tratados com HU comparados 
a indivíduos controles. Correlação positiva foi detectada entre IL-27 e IL-37 em 
pacientes HbSS com e sem tratamento com HU. Em relação aos experimentos 
in vitro, verificamos que a produção de IL-8 foi significativamente inibida em 
  
 
 
neutrófilos e monócitos pré-tratados com IL-27 e IL-37, apesar da adição de 
heme. 
Conclusão: Os resultados mostraram que a IL-27 e IL-37 estão elevadas em 
pacientes com AF sem tratamento com HU. Estas citocinas podem exercer um 
papel regulatório nas vias pró inflamatórias, como sugerido pelos experimentos 
in vitro. A ação destas citocinas é provavelmente suficiente para prevenir danos 
celulares e teciduais mais tardios, mas não tem efeito na prevenção da  
inflamação. Assim, IL-27 e IL-37 poderiam ter um potencial terapêutico 
contribuindo para a diminuição das complicações associadas com a elevação do 
heme, como ocorre na AF e outras anemias hemolíticas. 
 
 
 
Palavras chaves: Inflamação, anemia falciforme, IL-27, IL-37, hidroxiureia, 
heme.  
  
 
 
ABSTRACT 
Background and objective: Inflammation has been implicated in the pathogenesis 
of most complications seen in Sickle cell anemia (SCA) patients. This project 
aimed to evaluate serum levels of two newly discovered anti-inflammatory 
cytokines IL-27 and IL-37 and some pro-inflammatory cytokines among Brazilian 
SCA patients that are hydroxurea-naive and compared with hydroxyurea-treated 
patients and HbAA controls. Furthermore, to demonstrate the effect of IL-27, IL-
37 and heme on in vitro secretion of IL-8 in human neutrophils and monocytes. 
 Methods: It is a cross-sectional study of 82 consenting SCA (35 hydroxyurea-
naïve HbSS and 47 hydroxyurea-treated HbSS) patients in steady state and 49 
HbAA consenting individuals. Their clinical details were obtained by interview and 
from patients’ records. The serum levels of IL-27, IL-37, TGF-β, TNF-α, IL-1β, IL-
6 and IL-8 were quantified by ELISA. Neutrophils and monocytes were isolated 
from healthy controls, cultured separately without or with cytokines (IL-27 and IL-
37) and heme. The pro-inflammatory cytokines in the supernatant were detected 
by ELISA, 
Results: Serum levels of IL-27, IL-37, IL-1β, IL-6 and IL-8 in hydroxyurea- naïve 
SCA patients were significantly elevated compared to HbAA controls There was 
no significant difference in the serum levels of both anti- and pro-inflammatory 
cytokines except IL-8 in the HU-treated SCA patients compared to controls. IL-
27 and IL-37 were positively correlated in both HU-naive and hydroxyurea-treated 
HbSS patients. In vitro IL-8 production by IL-27 and IL-37 pre-treated neutrophils 
and monocytes was significantly inhibited despite addition of heme. 
Conclusions: Our findings show that IL-27 and IL-37 are elevated in HU-naïve 
patients. The study support that the use of HU did not significantly alter serum 
  
 
 
levels of anti- and pro-inflammatory cytokines except IL-8 in SCA patients. IL-27 
and IL-37 may play a regulatory role on the pro-inflammatory pathways, as 
suggested by the in vitro studies. This role is probably sufficient to prevent further 
cellular or tissue damage but not potent enough to prevent inflammation.  Thus, 
IL-27 and IL-37 may be potential immuno-targets to ameliorate complications 
associated with elevated heme as seen in SCA and other hemolytic anemias. 
 
 
Keywords: Inflammation, sickle cell anemia, IL-27, IL-37, hydroxyurea, heme.  
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1. INTRODUCTION 
1.1. Definition of Sickle Cell Anemia 
Sickle cell disease (SCD) is a major public health problem in the world.  Sickle 
cell disease (SCD) represents a group of inherited red blood cell disorder 
characterized by the presence of HbS gene in combination with other abnormal 
hemoglobin gene in homozygote, heterozygote or compound heterozygote 
states. The term sickle cell anemia (SCA) refers to the homozygous inheritance 
of HbS gene; and represents the most severe and most common form of SCD. It 
is usually mild with hemoglobin SC (HbSC) but a spectrum of clinical course is 
observed when there is co-inheritance with β-thalassemias. The severity is 
known to be mild with HbSβ+ and similar in HbSS and HbSβ0 (1). The resultant 
sickle hemoglobin (HbS) has its negatively charged hydrophilic glutamic amino 
acid replaced by hydrophobic valine at the 6th position of the hemoglobin beta 
globulin chain (1, 2). The inheritance of the mutant hemoglobin with normal 
hemoglobin results in the sickle cell trait (1-3).  
The mutant HbS gene originated in sub-Saharan Africa, but its distribution is 
now global. Piel et al (2013) using detailed geo-referenced data estimated that 5 
476 000 HbAS neonates and 312 000 SCA neonates were born in 2010. The 
prevalence of the deleterious gene ranges from 1.1% to 9.8% for HbAS and from 
0.8 to 60 per 100,000 live births SCD in different regions of Brazil (1, 2). Data 
from the national neonatal screening of SCD in Brazil, 2010, the prevalence of 
SCD was 1 per 650, 1 per 1,400 and 1 per 4,000 live births in Bahia, Pernanbuco 
and Sao Paulo respectively (4).  
The quality of life and longevity of patients with sickle cell anemia (SCA) is 
determined by various complications each patient experiences. Based on the 
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predominant pathophysiology, the complications of SCA are classified into two 
sub-phenotypes, the first group is characterized by hemolytic endothelial 
dysfunction and the second by vaso-occlusion (5). The complications are 
influenced by percentage of fetal hemoglobin (HbF), which varies with βs globin 
haplotypes, presence of alpha thalassemias and other genetic modifiers (3).   
 
1.2. Pathophysiology of sickle cell anemia: 
It is still not well elucidated why SCA, a disease with a single missense 
mutation in a gene whose expression is restricted to the erythroid lineage, is 
characterized by a wide spectrum of clinical manifestations. The sickle gene 
mutation in SCA is a single base change from adenine to thymine (GAG to GTG) 
on the 17th nucleotide of the β globin gene. This mutation results in the 
replacement of the hydrophilic glutamate by hydrophobic valine at the sixth amino 
acid residue of the β-globin polypeptide chain (6, 7). The human hemoglobin is a 
tetramer of   two pairs of identical peptide chains (α-like and β-like) coded by 
distinct genes. The genes of the β-globin gene cluster (ε, Gγ, Aγ, δ and β) are 
present on chromosome 11 in the same order in which they are expressed during 
ontogenic development. The β- locus control region (β–LCR) is a major regulatory 
element located far upstream  of the genes of the cluster that is necessary for the 
high level of expression of those genes. The genes of the α-globin gene cluster 
(ζ, α1 and α2) are present on chromosome 16, also in the same order in which 
they are expressed during ontogenic development. During fetal life, HbF (α2γ2) 
is the predominant type of hemoglobin. The hemoglobin switching refers to the 
developmental process that leads to the silencing of gamma-globin gene 
17 
 
 
 
expression and the reciprocal activation of adult β-globin gene expression. This 
results in the replacement of HbF by HbA (α2β2) as the predominant type of 
hemoglobin in adult life with about 2-5% of HbA2. This is the thrust for the use of 
hydroxyurea (HU) in the management of SCA thereby increasing the level of HbF 
and ameliorating the clinical severity of SCA (8, 9).    
Patients with SCA begin to manifest symptoms about 6 months of life, 
during which time there is a completion of switch from the HbF to the abnormal 
adult hemoglobin. (5, 7) The fetal hemoglobin is related to the beta globin 
haplotype and correlates to the clinical course of SCA. The beta hemoglobin 
haplotypes in SCA include Senegal, Benin, Bantu, Cameroun and the Arab-
Indian (10-12). The Senegal and Arab haplotypes are associated with the highest 
HbF levels, milder clinical manifestations of SCA and with lower occurrence of 
organ damage. The Benin and Cameroun haplotypes are associated with 
intermediate levels of HbF and clinical severity.  However, the Bantu haplotype 
is associated with the lowest levels of HbF and consequently with the worse 
clinical course. However, some studies have shown that the risk of acute chest 
syndrome, pain crisis and infections may be similar in individuals with the Benin 
and Bantu haplotypes (3, 12). 
The mechanisms involved in the pathophysiology of sickle cell anemia are 
complex and multifactorial. The abnormal globin chain polymerizes resulting in 
abnormal sickle hemoglobin molecule particularly during deoxygenation. In 
deoxygenated state, the sickle mutation leads to instability of the hemoglobin 
molecule resulting in hemoglobin polymerization (gelation), tactoid formation, 
RBC rigidity and subsequent red blood cell (RBC) membrane damage (Figure 1). 
This results in cellular dehydration, hemolysis, nitric oxide (NO) depletion, 
18 
 
 
 
secretion and activation of inflammatory markers and increased propensity for 
thrombo-embolic phenomenon (7, 13). 
The gelation theory emphasizes that during deoxygenation, the delay time 
of gelation is inversely proportional to about 30th power of the deoxygenated Hb 
concentration within the RBC. Therefore, if delay time of gelation is shortened, 
polymerization and vascular effect would be avoided and any factor that may 
cause a prolonged delay time would predispose to gelation and vaso-occlusion 
(5, 13-16). Alteration of pH (acidosis), oxygen tension (low), temperatures 
(extreme), erythrocyte 2, 3 diphosphoglycerate (DPG) levels (low) among others. 
are known to promote HbS polymerization (17). 
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Figure 1: The pathophysiology of sickle cell anemia. The HbS mutation, HBB 
glu6val, leads to β-globin chains that, when incorporated into hemoglobin 
tetramers with normal α-globin chains, produce a sickle hemoglobin, HbS, which 
can undergo reversible polymerization when deoxygenated. The sickle polymer 
injures the erythrocyte and eventually produces irreversible membrane damage. 
These cells have a shortened life span (hemolysis), some of which occurs 
intravascularly consuming nitric oxide (NO). Arginase released from Sickle 
erythrocytes favors the biosynthesis of ornithine hence NO becomes depleted 
and worsens vaso-occlusion. (From Steinberg 2008)(18). 
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1.3. Inflammation in sickle cell anemia: 
  Sickle cell anemia has been long recognized as a chronic inflammatory 
disease. Evidences have shown that though the mutation in SCA affect the 
erythrocytes, other cells - leukocytes, endothelial cells and platelets play 
important roles in the pathophysiology of this disease, Figure 2 (19). Neutrophils 
are the most abundant immune cells in the circulation and have a critical role in 
the innate immunity. High neutrophil count has been positively correlated with 
severe clinical manifestations, painful crises, early death, silent infarcts, 
hemorrhagic strokes, and acute chest syndrome (ACS) in SCA patients (20, 21, 
22). Reduction in neutrophil count is beneficial for SCA patients as seen in those 
on HU, who have marked reduction in the frequency of bone pain episodes and 
ACS (23). Effect of HU include increase HbF expression, increase NO synthesis, 
reduction of vascular cellular adhesion molecule-1 (VCAM-1) levels in plasma 
and reduction of RBCs to adhere to endothelial cells. Besides neutrophilia in SCA 
patients, the neutrophils are activated and HU has been reported to suppress the 
activation and recruitment of these cells (24, 25). 
 Platelets have inflammatory property in addition to being pivotal to 
coagulation process. Platelet activation is enhanced in SCA patients under 
steady state conditions and even further during vaso-occlusion crisis (VOC) (26, 
27). The activated platelets promote adhesion of sickle RBCs to endothelial cells 
by secreting thrombospondin, hence may contribute to thrombosis and 
pulmonary hypertension in SCA (28).  Platelets, that are increased as well as 
been activated in SCA, form aggregates with neutrophils and monocytes. These 
aggregates are elevated in SCA patients compared to controls and their inhibition 
21 
 
 
 
of formation of such aggregates could be protective against chronic inflammation 
and certain complications (29).  
Similarly, monocytes are increased, activated and promote inflammation 
in SCA patients. Monocytes from SCA patients activate endothelial cells through 
the nuclear factor kappa B (NF-kB) pathway and enhance expression of adhesion 
molecules including ICAM-1, VCAM-1, E-selectin, thus promoting adhesion of 
mononuclear leukocytes to endothelial cells.(30, 31). Leukocytes adhesion is 
enhanced by pro-inflammatory cytokines produced by monocytes. Evidence exist 
that blocking the tumor necrosis factor (TNF)-α and IL-1β from monocytes by 
neutralizing antibodies abrogated the increased expression of E-selectin in 
endothelial cells. (30, 31). 
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Figure 2: Inflammation in Sickle cell disease. SCD has been recognized as a 
chronic inflammatory disease. Multiple cell types and molecules are involved in 
its inflammatory pathways. Hemolysis of RBCs leads to the release of heme into 
the circulation, which can activate endothelial cells through the TLR4 pathway 
and induce PlGF release from RBCs. PlGF activates monocytes, leading to the 
production of pro-inflammatory cytokines TNF-α and IL-1β. The adhesion of 
platelets or sickle RBCs can also activate endothelial cells, producing increased 
expression of adhesion molecules including ICAM-1, VCAM-1, P-selectin, and E-
selectin, and thus promoting the recruitment of neutrophils. iNKT cells exhibit an 
activated phenotype and contribute to pulmonary dysfunction in SCD by 
producing IFN-γ and inducing CXCR3 chemokines. Platelets can form 
aggregates with circulating leukocytes, including neutrophils and monocytes. 
Activated neutrophils roll and adhere to the endothelium, and initiate VOC by 
capturing sickle RBCs. Heme can also induce NET formation, which promotes 
acute pulmonary injury in SCD. Another damage-associated molecular pattern 
released from activated immune cells and necrotic cells, HMGB1, is a key player 
in promoting inflammation in SCD through activation of TLR4 signalling pathway. 
HMGB1, high mobility group box 1; iNKT cell, invariant natural killer T cell. (From 
Dachuan Zhang et al. 2016)(19). 
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1.4. Cytokines in sickle cell anemia 
Pro-inflammatory cytokines play critical role in the pathophysiology of 
SCA. SCA patients exhibit higher levels of TNF-α, IL-1β, IL-6, IL-3, IL-10, IL-17. 
Following hemolysis, free hemoglobin, heme and other products are released. 
Placental growth factor (PlGF), from the red cells activate monocytes to secrete 
IL-8 and other cytokines. These cytokines activate endothelial cells and 
leukocytes via the NF-kB pathways resulting in increased expression of 
endothelial adhesion molecules such as ICAM-1, VCAM-1, E-selectin. This leads 
to leukocyte adhesion and triggers vaso-occlusion (32) Interleukin-8 (IL-8) is a 
pro-inflammatory member of the CXC chemokine family, involved in both 
endothelial cell proliferation and angiogenesis (33). Several types of cells, such 
as neutrophils, endothelial cells, macrophages and fibroblasts, produce IL-8 (34).  
IL-8 plays a role in the re-arrangement of the cytoskeleton, changes in 
intracellular Ca++ levels, activation of integrins and promotion of protein-granule 
exocytosis and the respiratory burst (35).  IL-8 require CXCR1 and CXCR2 as 
receptors, which are expressed mainly by neutrophils, to enhance neutrophil 
recruitment and function (33). 
Tumor necrosis factor-α (TNF-α) is another pro-inflammatory cytokine 
produced mainly by monocytes/macrophages and other cells, such as T-cells, 
smooth muscle cells, adipocytes and fibroblasts. The main function of  TNF-α is 
to stimulate tumor necrosis and regression in vivo  (34). Its actions are mediated 
by tumor necrosis factor receptors (TNFR 55 and TNFR 75), which are present 
on the membrane of several types of cells, excluding RBCs (36). Synergistically, 
IL-8 and TNF-α induce increased adhesion of RBC and leukocytes to the vascular 
endothelium, and this adhesion can cause vaso-occlusion and local hypoxia (37). 
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Local hypoxia will further worsen vaso-occlusion leading to vicious cycle.  
Increasing evidences have shown that IL-8 and other cytokines are elevated in 
SCA patients during VOC as well as in steady state (37-42). Contrarily, other 
studies have reported that IL-8 levels was not different in SCA patients during 
VOC or steady state (43, 44). Result with use of HU is not clear-cut. Some 
researchers reported increased serum levels of circulating IL-8 in HU-treated 
patients (38). Others reported conflicting results, demonstrating that patients 
undergoing HU therapy displayed significantly lower plasma levels of IL-8 (41). 
Other studies showed that HU did not significantly alter plasma TNF-α 
concentrations (41, 44) These suggest that increased levels of circulating IL-8 
and TNF-α are associated with increased hemolysis, vascular occlusion and 
inflammation. Hydroxyurea is a potent inducer of HbF and the only FDA-approved 
therapy for SCA. Hydroxyurea has multiple mechanisms by which it produces its 
clinical effects.  The recommended escalation of HU is associated with reduction 
of neutrophils and thrombocytosis in SCA thereby reducing inflammation. 
Reports show that short-term administration of HU ameliorates VOC in a SCD 
murine model via NO-mediated pathways. 
One study observed higher plasma concentrations of IL-1β in Saudi 
Arabian SCA patients during both steady state and painful crises than in control 
subjects. However, higher levels were observed during the steady state than 
during painful crises (45). Similarly, plasma IL-1β levels were reported to be good 
predictor of stroke outcome and that high plasma IL-1β levels were associated 
with protection against stroke development in juvenile SCA patients with altered 
transcranial Doppler studies (46). Another study among SCA patients, found a 
positive correlation between elevated serum IL-18 levels and classic danger 
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signals, including uric acid and lactic dehydrogenase (LDH) (47). LDH and other 
markers of hemolysis were reported to be linked to oxidative stress. The release 
of reactive oxygen species (ROS) enhances VOC by classical endothelial 
activation and ROS-mediated activation of inflammasome via membrane 
receptors. Inflammasome, a multiprotein complex involved in the activation of 
other plasma proteins such as caspase-1, is formed at the junction of many 
inflammatory molecules in response to danger signals (48).  
The anti-inflammatory cytokines that are known are fewer. Interleukin-10 
is an anti-inflammatory cytokine, secreted by activated CD8+ T cells as well as 
activated T-helper (TH0, TH1 and TH2) cells, B-lymphocytes, mast cells and 
lipopolysaccharide-activated monocytes (49). IL-10 mainly inhibit the synthesis 
of pro-inflammatory cytokines such as TNF-α, GM-CSF, IL-1, IL-6, IL-8 and IL-
12. IL-10 also inhibits the proliferation of TH1 cells, decreasing cytolytic function 
and the secretion of TH1 cytokines and facilitating the development of a TH2 
response (32). The role of anti-inflammatory cytokine in SCA patients is 
conflicting. While some researcher found elevated IL-10 levels among HU-treated 
Brazilian SCA patient, Cerqueira et al. did not find a significant difference in the 
IL-10 level between the SCA and HbAA controls. However, these patients were 
HU-naive (41, 47). Another anti-inflammatory cytokine, IL-4, was observed to be 
elevated during VOC and during the steady-state (50, 51). In 2000, an 
investigation of the TH2 cytokine levels in SCA patients revealed that plasma IL-
4 levels were significantly higher among steady-state HbSS patients than HbAA 
individuals. In addition, the ratio of plasma IL-2 to IL-4 and IFN-γ to IL-4 were 
significantly lower in HbSS patients than in the other groups (51).  
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 From the aforementioned, it is obvious that inflammatory markers such as 
pro-inflammatory cytokines, chemokines and adhesion molecules are being 
extensively studied in SCA; however, only a few studies exists on the anti-
inflammatory aspect of the immune response. This stimulated the conception of 
these recently characterized anti-inflammatory cytokines (IL-27 and IL-37) in SCA 
patients. Though no existing report of evaluation of these cytokines in patients 
with SCA, recent works have described their important participation in modulation 
of chronic inflammatory diseases (52-54). The duo of IL-27 of the IL-12 family 
and IL-37 of the IL-1 family member have received special attention due to their 
potent anti-inflammatory and potential therapeutic use in patients with  chronic  
inflammatory disorder such as atherosclerosis, colitis, and rheumatoid arthritis 
(52, 53, 55-57). Dendritic cells and macrophages produce interleukin-27 (IL-27) 
after stimulation via Toll-like receptors (TLR2, TLR4 and TLR9). IL-27 is 
composed of two subunits, Epstein Bar induced gene EBI3 and p28, which bind 
to a specific receptor made up of the WSX-1 subunits (known as IL-27R) and 
gp130 (58, 59). In mice, the activation of naive CD4 + T cells in the presence of 
IL-27 or transforming growth factor-β (TGF-β) results in their differentiation into 
IL-10 producing Tr1 cells, a potent suppressor of inflammation. In addition, IL-27 
is capable of inhibiting the differentiation of naive CD4 + T cells to Th17 and / or 
Treg Foxp3 + (60). Some researchers have shown the potential inhibitory role of 
IL-27 in inflammatory diseases such as autoimmune encephalomyelitis, 
rheumatoid arthritis and uveitis (61-63). In ApoE-/- mice, an experimental 
atherosclerosis model, it was shown that the adoptive transfer of Tr1 IL-10 
promotes the reduction of lesion formation. In addition, the authors verified the 
co-localization of EBI3 and p28, subunits of IL-27, in human atherosclerotic 
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lesions (52).  In mice induced zymosan peritonitis, the early administration of IL-
27 was able to control mobilization and recruitment of neutrophils into the 
peritoneal cavity as well as decreased chemokines such as Monocyte 
Chemoattractant Protein-1 (MIP-1) and Macrophage Inflammatory Protein-1α  
(MIP-1α) (64). Thus, buttressing their anti-inflammatory role. Li et al. recently 
demonstrated the constitutive expression of IL-27 receptor complex on human 
neutrophils and that IL-27 mainly down modulate human neutrophil function (65). 
Similarly, other researchers demonstrated that IL-37 suppresses TNF-α-induced 
neutrophil activation and reduces pro-inflammatory cytokines and chemokine 
production from Kupffer cells and hepatocytes, hence this cytokine was reported 
to be protective for hepatitis (66). 
The biological role of IL-37 (IL-1F7) is still unclear, but studies in murine 
models have shown their marked ability to inhibit inflammatory response (67, 68). 
IL-37 transgenic mice are less susceptible to LPS-induced shock and to dextran 
sulfate-induced colitis (69).  Unlike IL-27, the effect of IL-37 is likely independent 
of IL-10, since receptor blockade of this cytokine receptor (IL-10R) does not 
reverse the protection induced by IL-37 (69). The expression of IL-37 in 
macrophages and epithelial cells decreases the secretion of pro-inflammatory 
cytokines, whereas the silencing of the IL-37 gene in human cells led to a greater 
expression of these cytokines. Transient expression of IL-37 in the liver of mice 
protects against hepatitis induced by concanavalin-A (67).  The anti-inflammatory 
properties of IL-37 were also demonstrated in vitro when RAW macrophages 
incubated with IL-37 produced reduced concentrations of pro-inflammatory 
cytokines such as IL-1α, IL-6, TNF-α, and CXCL2 after activation by LPS. A 
similar reduction in cytokine production was observed in THP-1 macrophages 
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and in epithelial cells stimulated with LPS and IL-1 (67).  Similarly, Sharma and 
colleagues (2008) showed that the silencing of endogenous IL-37 in endothelial 
and muscular cell lines induced a significant increase of 13 pro-inflammatory 
cytokines, including IL-1α, IL-1β, IL-6, TNFα and GM-CSF (68). Participation of 
IL-37 in the anti-inflammatory response was also evidenced in a study with colon 
extract cultures in which the presence of this cytokine was shown to reduce the 
production of TNF-α and IL-1β in vitro and in vivo, in addition to inducing a six-
fold increase in IL-10, an anti-inflammatory cytokine (69). Based on the potential 
anti-inflammatory role of IL-27 and IL-37 in chronic inflammatory disorders and 
lack of studies evaluating their role in SCA, this study aimed to evaluate the 
serum levels of IL-27, IL-37 and other cytokines in Brazilian hydroxurea-naïve 
SCA patients compared with hydroxyurea-treated patients and HbAA controls. In 
addition, to demonstrate the anti-inflammatory role of these cytokines in 
monocyte and neutrophil cultures stimulated by heme. 
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2. OBJECTIVES 
2.1. General objective 
To evaluate the inflammatory response in sickle cell anemia patients and 
to evaluate the inhibitory role of IL-27 and IL-37 on inflammation in heme-
stimulated cells in vitro. 
 
2.2. Specific objectives   
• To determine the serum concentration of pro- and anti-inflammatory 
cytokines in hydroxyurea-naïve and hydroxyurea-treated sickle cell 
anemia patients; and HbAA controls. 
• To evaluate the effect of IL-27 and IL-37 on cytokine production by heme-
stimulated cells in vitro.  
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ABSTRACT 
Background and objective: Inflammation has been implicated in the pathogenesis of 
most complications seen in Sickle Cell Anemia (SCA) patients. We aimed to evaluate 
serum levels of two newly discovered anti-inflammatory cytokines (IL-27 and IL-37) and 
some pro-inflammatory cytokines among Brazilian SCA patients that are hydroxurea 
(HU)-naive and compared with hydroxyurea-treated patients and healthy controls 
(HbAA).  Furthermore, we demonstrated the effect of IL-27, IL-37 and heme on in vitro 
secretion of IL-8 in human neutrophils and monocytes. 
Methods: It is a cross-sectional study of 82 consenting SCA (35 HU-naive HbSS and 47 
HU-treated HbSS) patients in steady state and 49 HbAA consenting individuals. Their 
clinical details were obtained by interview and from patients’ records. The serum levels 
of IL-27, IL-37, TGF-β, TNF-α, IL-1β, IL-6 and IL-8 were quantified by ELISA. Neutrophils 
and monocytes were isolated from healthy controls, cultured separately without or with 
cytokines (IL-27 and IL-37) and heme. Using ELISA, the concentration of IL-8 in the 
supernatant was detected.  
Results: Serum levels of IL-27, IL-37, IL-1β, IL-6 and IL-8 in HU-naive SCA patients were 
significantly elevated compared to HbAA controls. There was no significant difference in 
the serum levels of the anti- and pro-inflammatory cytokines in HU-treated SCA patients 
compared to controls except IL-8 level that was higher in both HU-naïve and HU-treated 
SCA patients than the controls. IL-27 and IL-37 were positively correlated in both HU-
naive and hydroxyurea-treated HbSS patients. In vitro IL-8 production by IL-27 and IL-
37 pre-treated neutrophils and monocytes was significantly inhibited despite addition of 
heme. 
Conclusions: Our findings show that IL-27 and IL-37 are elevated in HU-naïve patients. 
The study support that the use of HU did not significantly alter serum levels of anti- and 
pro-inflammatory cytokines except IL-8 in SCA patients. IL-27 and IL-37 may play a 
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regulatory role on the pro-inflammatory pathways, as suggested by the in vitro studies. 
This role is probably sufficient to prevent further cellular or tissue damage but not potent 
enough to prevent inflammation.  Thus, IL-27 and IL-37 may be potential immuno-targets 
to ameliorate the complications associated with elevated heme as seen in SCA and other 
hemolytic anemias. 
 
 
Keywords: Inflammation, sickle cell anemia, IL-27, IL-37, hydroxyurea, heme.   
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1. Introduction 
Sickle Cell Anemia (SCA) is an inherited disease of global health burden 
characterized by chronic hemolysis and chronic end organ damage (1, 2). Based on the 
predominant pathophysiology, the complications in SCA patients are classified into 
hemolytic endothelial dysfunction and vaso-occlusion sub-phenotypes (3). Chronic 
inflammatory state in SCA patients is associated with high expression of markers of 
inflammation such as adhesion molecules and cytokines because of complex 
interactions among endothelial cells, erythrocytes, leukocytes and platelets (4). 
Following hemolysis, hemoglobin, heme and other products are released. Placental 
growth factor (PlGF) from the red cells activate monocytes to secrete IL-8 and other 
cytokines. These cytokines activate endothelial cells and leukocytes via the NF-kB 
pathways resulting in increased expression of endothelial adhesion molecules such as 
ICAM-1, VCAM-1, E-selectin (5). This leads to leukocyte adhesion and subsequently 
triggers vaso-occlusion (6). Several types of cells, such as neutrophils, endothelial cells, 
macrophages and fibroblasts produce IL-8, a CXC chemokine family member, involved 
in neutrophil recruitment/function, endothelial cell proliferation and angiogenesis (7-9). 
Tumor necrosis factor-α (TNF-α), produced mainly by monocytes/macrophages and 
other cells, such as T-cells, smooth muscle cells, adipocytes and fibroblasts, stimulates 
necrosis in tumors (8, 10). IL-8 and TNF-α induce increased adhesion of erythrocytes 
and leukocytes to the vascular endothelium, and this adhesion can cause vaso-occlusive 
crisis (VOC) and local hypoxia (11).  
 Several studies have shown that SCA patients display higher levels of IL-8 as 
well as other cytokines during VOC and steady state compared to controls but a few did 
not find a statistical difference (11-18). Results with use of hydroxyurea are not clear-cut. 
Some researchers reported increased levels of circulating IL-8, some reported 
significantly lower levels of IL-8 while others reported unaltered TNF-α level in 
hydoxyurea (HU)-treated patients (12, 15, 18). Similarly, a higher plasma concentration 
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of IL-1β observed during both steady state and painful crises than in control subjects is 
demonstrated to be a good predictor of stroke outcome in SCA patients (19, 20). This 
increase in pro-inflammatory cytokines leads to imbalance between the pro- and anti-
inflammation with the pro-inflammatory been favored. Thus, endothelial activation is 
worsened and the vicious cycle continuous. The pattern of anti-inflammatory cytokines 
in SCA are similar to the pro-inflammatory as studies show that IL-10 and IL-4 may be 
higher, lower or unchanged in SCA compared to controls (15, 21-23). 
Only a few studies evaluated the role of anti-inflammatory cytokines in SCA and 
there are no studies on two recently characterized anti-inflammatory cytokines, IL-27 and 
IL-37. However, recent works have described the importance of IL-27 and IL-37 in 
modulation of chronic inflammatory disease (24-26). Interleukin-27 of the IL-12 family 
and IL-37 of the IL-1 family have received special attention due to their potent anti-
inflammatory and potential therapeutic use in patients with atherosclerosis, systemic 
lupus erythematosus (SLE), rheumatoid arthritis, ankylosing spondylitis and others (24, 
25, 27-29). Dendritic cells and macrophages produce IL-27 after stimulation via TLR2, 
TLR4 and TLR9 (30, 31). Naive CD4+ T cells in the presence of IL-27 or TGF-β 
differentiates into IL-10 producing Tr1 cells, a potent suppressor of inflammation. In 
addition, IL-27 is capable of inhibiting the differentiation of naive CD4+ T cells in Th17 
and/or Treg Foxp3+ (32). IL-27 has a potential inhibitory role in some inflammatory 
diseases such as colitis, multiple sclerosis, atherosclerosis, autoimmune disorders and 
others (33-35). Most of these studies focus on the role of IL-27 in regulating adaptive 
immune cells, but more recently, researchers have demonstrated that IL-27 and IL-37 
modulate the functions of neutrophils thereby suppressing the neutrophil activation and 
production of pro-inflammatory cytokine (36, 37). The biological role of IL-37 is still 
unclear, but its marked ability to inhibit inflammation is worth evaluating in SCA (38, 39). 
The expression of IL-37 in macrophages and epithelial cells decreases the secretion of 
pro-inflammatory cytokines, whereas the silencing of the IL-37 gene in human cells led 
to a greater expression of these cytokines (38).  Based on the potential anti-inflammatory 
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role of IL-27 and IL-37 in chronic inflammatory disorders and lack of studies evaluating 
their role in SCA, this study aimed to evaluate the serum levels of IL-27, IL-37 and other 
cytokines in Brazilian HU-naive SCA patients compared with HU-treated patients and 
normal HbAA controls. In addition, to demonstrate the effect of IL-27 and IL-37 on in vitro 
production of IL-8 in monocyte and neutrophil cultures stimulated with heme. 
2. Materials and methods 
2.1. Study participants 
The study was a cross-sectional study comprising eighty-two (82) previously diagnosed 
adult HbSS patients on follow up at the Hematology and Hemotherapy Center of 
Pernambuco (HEMOPE), Recife. The control group consisted of forty-nine (49) healthy 
adult (HbAA) individuals from the same region and with same ethnical characteristics. 
Patients who had been previously diagnosed with HbSS by alkaline electrophoresis, 
High Performance Liquid Chromatography (HPLC) and solubility test were included, if in 
steady state. Steady state was defined as stable clinical state for three (3) months, 
without signs or symptoms of infection, pain, other acute episode suggestive of crisis or 
blood transfusion. Those individuals with any of the following were excluded: pregnancy; 
infections; acute or chronic inflammatory disease or use of immunosuppressant in the 
last two weeks; malignancies and SCA in acute crisis. The participants who fulfilled the 
above criteria were grouped as follows: HU-naive group (HbSS) – SCA patients who 
were not taking hydroxyurea; HU-treated group (HbSSHU) – SCA patients on 
hydroxyurea; and Hemoglobin AA control group (HbAA control) – Hemoglobin AA 
individuals without SCA or trait. 
All participants signed the consent form and the questionnaire was filled 
adequately by interview and from patient’s notes. Some of the details obtained based on 
the questionnaire were bio-data and complications of SCA suffered. Subsequently, 5mL 
of venous blood was collected into plain sample tube from each patient and control in 
addition to the routine blood samples for complete blood count. The samples were 
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centrifuged and the sera were stored in aliquots at -80oC until analyzed.  When the 
collection was complete, the samples were then transported in dry ice to UNICAMP, 
Campinas, southeast Brazil and were stored at -80oC until cytokines were assayed. 
The study was approved by ethical committees of both UNICAMP, Campinas and 
HEMOPE, Recife (CAAE: 52941315.6.0000.5404) and all participants gave written 
consent. 
2.2. Hematological analysis 
Hematological analysis was performed using an automated cell counter (Abbott 
cell Dyn Ruby analyzer, Illinois, U.S.A.). The hemoglobin S, F and A2 were determined 
by HPLC (BIO-RAD variant II, CA, U.S.A.).  
2.3. Quantification of plasma concentrations of pro-and anti-inflammatory cytokines  
The serum levels of the IL-1β, TNF-α, IL-6, IL-8, TGF-β, IL-27 and IL-37 were 
quantified by enzyme-linked immunosorbent assay (ELISA) using commercial kits (R&D 
Systems, Minneapolis, MN or Biolegend, San Diego, CA, USA) according to 
manufacturer's instructions. 
2.4. Isolation of Peripheral Blood Mononuclear Cells (PBMCs) 
 Peripheral blood was collected from five (5) healthy controls (80-100mL) into 
sodium heparin tubes. The samples were centrifuged on a ficoll-hypaque solution 
(density 1.077; 400g for 30 minutes at room temperature) and the mononuclear cells 
(layer over the ficoll-hypaque solution) were transferred to another 15mL falcon tubes. 
PBMCs were washed twice with RPMI 1640 medium (300g for 10 minutes at 4°C) and 
re-suspended in supplemented RPMI 1640 medium (10% fetal bovine serum + L-
glutamine [2mM] + gentamicin [5μg/mL] + sodium pyruvate [1µM]). Cells were quantified 
and subjected to monocyte isolation. The buffy coat layer over the red blood cells was 
transferred to a 15mL falcon tube for neutrophil isolation. 
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2.5. Isolation of monocytes 
 Monocytes were isolated using the Monocyte Isolation Kit II (Miltenyi Biotec, 
Germany) kit according to the manufacturer's instructions. Briefly, PBMCs were re-
suspended at a concentration of 1x107 cells in 80μL of PBS-B-E buffer (PBS-BSA [0.5%] 
+ EDTA [2mM]) and incubated for 10 minutes at 4°C with a mixture of biotinylated 
antibody against CD16 (neutrophils and NK cells), CD19 (B lymphocytes), CD56 (NK 
cells), CD123 (dendritic cells and basophils) and CD235a (Glycophorin A, Erythrocytes). 
After incubation, the anti-biotin antibody coupled to magnetic beads were added and the 
cells incubated for 15 minutes at 4°C. After washing with PBS-B-E (300g, 10 minutes, 
4°C), the cells were re-suspended in 500μL of buffer and passed through a magnetic 
separation LD (Miltenyi Biotec, Germany) column. The fraction not retained by the 
column (monocytes) was collected, centrifuged (300g, 10 minutes, 4°C) and re-
suspended in supplemented RPMI 1640 medium at a concentration of 1x106 cells/mL. 
Monocytes obtained after separation were used in the experiments described below. The 
purity of the isolated monocytes was evaluated by flow cytometry and was always >95%. 
 
2.6. Isolation of peripheral blood neutrophils 
 After the supernatant containing mononuclear cells, plasma and Ficoll solution 
has been removed, the polymorphonuclear cells located in the buffy coat layer were 
transferred to a 15mL falcon tube. Then, the cells were re-suspended in red blood cell 
lysis buffer (NH4Cl 155mM, KHCO3 10mM and EDTA 1mM) and incubated at room 
temperature for 10 minutes. After a second wash, the number of cells was estimated and 
re-suspended in supplemented RPMI 1640 medium. Cell suspensions at a concentration 
of 1x106 cells per well were used for subsequent experiments. 
 
2.7. Neutrophils and monocytes cell cultures 
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Immediately after purification, neutrophils and monocytes in separate cultures 
were suspended in supplemented RPMI-1640 medium. Separate cultures of neutrophils 
and monocytes were subjected into 3 groups - cells without pre-stimulation; cells with 4 
hours of heme pre-stimulation followed by addition of cytokines (recombinant human, IL-
27 or IL-37) and cells with 4 hours of cytokine (IL-27 or IL-37) pre-stimulation and 
followed by addition of heme. Cell cultures were treated without or with 30μM heme 
(Sigma-Aldrich Co, U.S.A), 5ng/mL rhIL-27, 5ng/mL rhIL-37 and 10ng/mL rhTNF-α (all 
from R&D Systems, Minneapolis, MN, U.S.A). Neutrophil and monocyte cultures were  
incubated for 18 hours and 24 hours respectively at 37oC, in a 5% CO2 atmosphere. After 
incubation, cell cultures were centrifuged and the supernatant was collected for the 
measurement of IL-8 (a marker of inflammation) by ELISA according to manufacturer’s 
instructions. 
 
2.8. Statistical analysis 
GraphPad Prism Program, version 6 for Windows (San Diego, California, U.S.A) 
was used for data analysis. The normal distribution of the quantitative variables was 
verified by the Kolmogorov-Smirnov and Shapiro-Wilk tests. Continuous variables that 
had a non-normal distribution were expressed in median with interquartile range (IQR) 
and analyzed by the Kruskal-Wallis with Dunn’s multiple comparisons post-test for three 
or more independent groups. One-way ANOVA for repeated measures with Tukey post-
test was used to compare parameters obtained from in vitro experiments. Correlations 
were determined by Spearman’s rank correlation coefficient and the results were 
considered statistically significant when the probability was less than 5% (p<0.05). 
 
3. Results 
3.1. Demographic and hematological parameters of the participants 
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One hundred and thirty-one (131) adult participants were enrolled. The mean 
ages of the 35 hydroxyurea-naive SCA (HbSS) patients, (31.94±9.37years) and 47 
hydroxyurea-treated SCA (HbSSHU) patients, (30.64±8.26years) were higher than that 
of the 49 HbAA controls (24.73±4.66years). There were more males in the HbSS and 
HbSSHU groups. As expected, the red blood cells, hematocrit and hemoglobin were 
significantly higher in the HbAA controls than HbSS and HbSSHU groups (p<0.0001 for 
each comparison). The leukocytes, neutrophils, lymphocytes, monocytes and platelets 
were significantly higher in the HbSS group than in the HbAA controls. The demographic 
and hematological parameters are summarized in Table 1.  
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Table 1: Demographic and hematological parameters of participants 
Parameters 
HbSS  
(N=35) 
HbSSHU  
(N=47) 
HbAA  
(N=49) 
p value 
A B C A vs B A vs C B vs C 
Age (Years) 31.94 ± 9.37 30.64 ± 8.26 24.73 ± 4.66 NS < 0.001 < 0.001 
Male/female 23 / 12 24 / 23 18 / 31 NS NS NS 
RBC (x106/μL) 2.46 ± 0.72 2.48 ± 0.43 4.79 ± 0.60 NS < 0.0001 < 0.0001 
Hemoglobin (g/dL) 7.54 ±1.56 8.9 ± 1.4 13.8 ± 1.5 <0.05 < 0.0001 < 0.0001 
Hematocrit (%) 21.19 ± 4.54 24.25 ± 5.14 41.63 ± 4.42 NS < 0.0001 < 0.0001 
WBC (x103/μL) 10.72 ± 3.81 8.70 ± 2.84 6.72 ± 2.81 <0.05 < 0.0001 <0.05 
Neutrophils (x103/μL) 5.94 ± 2.75 4.56 ± 2.32 3.67 ± 2.13 NS 0.0007 NS 
Lymphocytes (x103/μL) 3.42 ± 1.51 3.03 ± 0.98 2.30  ± 0.82 NS < 0.0001 < 0.01 
Monocytes (x103/μL) 1.14 ± 0.60 0.92 ± 0.45 0.59 ± 0.90 NS < 0.0001 < 0.0001 
Platelets (x103/μL) 431.2 ± 168.2 335.2 ± 120.0 256.2 ± 53.82 NS < 0.001 < 0.001 
Hemoglobin F (%) 5.86 ± 4.47 7.74 ± 5.07 ND NS - - 
Hemoglobin S (%) 86.05 ± 5.14 88.29 ± 6.24 ND NS - - 
Hemoglobin A2 (%) 3.53 ±0.86 3.05 ±1.21 ND NS - - 
Reticulocytes (x103/μL)  275.40 ±116.40 271.10 ± 99.0 ND NS - - 
LDH (U/L) 704.10 ± 404.90 618.90 ± 370.20 ND NS - - 
The results expressed as mean ± SD.  NS= not significant; ND= not done; LDH = Serum lactate 
dehydrogenase, WBC = White blood cells, RBC = Red blood cells.  
 
3.2 Clinical data of participants 
Out of the 82 SCA patients, most, 72 (87.8%) had experienced bone pain crisis 
in their lifetime. Other complications reported were osteonecrosis, 17 (20.7%); acute 
chest syndrome, 6 (7.3%); pulmonary hypertension, 5 (6.1%); sequestration crisis, 6 
(7.3%); gallstone, 56 (68.3%); stroke, 16 (19.5%); persistent splenomegaly, 7 (8.5%); 
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chronic leg ulcers, 24 (29.3%); pneumonia, 36 (43.9%). In addition, 77 (93.3%) of them 
had had blood transfusion in the past. Of the 47 male SCA patients, 11 (23.4%) had 
experienced priapism in the past.  
 
3.3 Anti-inflammatory cytokine levels in sickle cell anemia patients and 
controls 
 The serum levels of the IL-27, IL-37 and TGF–β among the HU-naive SCA 
patients (HbSS), hydroxyurea-treated SCA patients (HbSSHU) and the control 
individuals (HbAA) are shown in Figure 1A-C. Interleukin 27 was significantly higher in 
the HbSS group than the HbAA controls (median [IQR]: 966.7 [677.9 - 11,154.0] vs. 
738.1 [470.0 – 1,706.0] pg/mL). Serum IL-27 was not significantly different between the 
HbSS and HbSSHU groups (median [IQR]: 966.7 [677.9 - 11,154.0] vs. 677.9 [490.2 – 
3,214.0] pg/mL). Similarly, the serum IL-37 level was significantly higher in the HbSS 
group than the HbAA control group (median [IQR]: 225.0 [33.9 – 1,648.0] vs. 55.76 
[22.63 – 179.0] pg/mL). There was no significant difference in IL-37 level between HbSS 
and HbSSHU (median [IQR]: 225.0 [33.9 – 1,648.0] vs. 111.2 [34.72 – 569.4] pg/mL, 
respectively). Serum levels of both cytokines were not significantly different between 
HbSSHU and HbAA groups (IL-27: 677.9 [490.2 – 3,214.0] vs. 738.1 [470.0 – 1,706.0] 
pg/mL and IL-37: 111.2 [34.72 – 569.4] vs. 55.76 [22.63 – 179.0] pg/mL, respectively). 
There was no significant difference in TGF-β levels among the HbAA, HbSS and 
HbSSHU (54,612.0 [45,274.0 – 69,600.0], 55,506.0 [41,717.0 – 73,497.0] and 53,839.0 
[41,614.0 – 69,359.0] pg/mL respectively). 
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Figure 1. Serum levels of anti-inflammatory cytokines IL-27 (A), IL-37 (B) and TGF-
β (C) in control individuals (HbAA control, n=49), hydroxyurea-naive (HbSS, n=35), 
hydroxyurea-treated (HbSSHU, n=47) patients. The horizontal lines represent median. 
Kruskal-Wallis with Dunn’s multiple comparisons post-test;  * p<0.05 
 
3.4 Pro-inflammatory cytokine levels in sickle cell anemia patients and 
controls 
 The serum levels of TNF-α, IL-1β, IL-6 and IL-8 among the HbSS patients 
HbSSHU and the HbAA groups are shown in Figure 2A-D. Interleukin-1β, IL-6 and IL-8 
were significantly higher in the HbSS (median [IQR]: 0.0 [0.0 - 17.53], 8.62 [4.7 – 57.08] 
and 26.48 [14.38 – 226.1] pg/mL respectively) than in the HbAA group (median [IQR]: 
0.0 [0.0 – 0.0], 3.59 [2.65 – 7.31] and 0.0 [0.0 – 38.72] pg/mL respectively). In addition, 
IL-8 was significantly higher in the HbSSHU (median [IQR]: 17.09 [12.97 – 40.12] pg/mL) 
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than in the HbAA group (median [IQR]: 0.0 [0.0 - 38.72] pg/mL). TNF-α, IL-1β and IL-6 
did not show significant difference in between HbSSHU and HbAA groups. Similarly, 
there was no significant difference in serum TNF-α level among the three groups. 
 
Figure 2. Serum levels of pro-inflammatory cytokines TNF-α (A), IL-1β (B), IL-6 (C) 
and IL-8 (D) in control individuals (HbAA control, n=49), hydroxyurea-naive (HbSS, 
n=35), hydroxyurea-treated (HbSSHU, n=47) patients. The horizontal lines represent 
median. Kruskal-Wallis with Dunn’s multiple comparisons post-test;  * p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001. 
                                                 
                                                                                             
3.5. Correlations of serum IL-37 and IL-27 in sickle cell anemia patients 
 Serum levels of IL-37 and IL-27 were strongly and positively correlated (p<0.0001 
and r=0.8639) in the SCA patients (HbSS and HbSSHU) (Figure 3).  
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 Figure 3. Correlation between circulating IL-27 and IL-37 levels among sickle cell 
anemia patients (Hydroxyurea- naive and treated patients) (n=82); Spearman 
correlation for non-parametric data; r = correlation coefficient. 
 
3.6. Effects of heme and cytokines on IL-8 production by neutrophils and 
monocytes 
  Using ELISA based quantitation of IL-8 (as a marker of inflammation) in the 
culture supernatant; we investigated the inflammatory effect of heme, IL-27, IL-37 and 
TNF-α (positive control), Figure 4. Separate neutrophil and monocyte cultures were 
stimulated with heme, IL-27, IL-37 and TNF-α for 18 and 24 hours, respectively. In 
monocyte cultures (Figure 4B), heme induced a significantly higher concentration of IL-
8 compared to the control (unstimulated, p<0.01). Neither IL-27 nor IL-37 induced the 
secretion of IL-8 from both neutrophils and monocytes.  
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Figure 4: In vitro production of IL-8 by neutrophils (A) and monocytes (B) from 
control individuals (n=5) after stimulation with heme, IL-27, IL-37 and TNF-α. US-
unstimulated/culture medium; HEME-30µM; IL-27- 5ng/mL; IL-37- 5ng/mL. One-way 
ANOVA for repeated measures with Tukey post-test; *p <0.01.  
3.7. Effects of IL-27 and IL-37 on IL-8 production by heme pre-stimulated 
neutrophils and monocytes 
We investigated the inhibitory effect of IL-27 and IL-37 in neutrophil and monocyte 
cultures, shown in Figure 5. After 4 hours of pre-stimulation of neutrophils with heme, IL-
37 significantly suppressed IL-8 production by the neutrophils (p<0.05) but IL-27 did not 
reach statistical significance, Figure 5A.  Neither IL-27 nor IL-37 significantly suppressed 
the inflammatory response induced by heme in monocyte cultures, Figure 5B.  
Figure 5. Effect of IL-27 and IL-37 on IL-8 production by heme pre-stimulated 
neutrophils (A) and monocytes (B) from control individuals (n=5). US-
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unstimulated/culture medium; HEME-30µM; IL-27- 5ng/mL; IL-37- 5ng/mL. One-way 
ANOVA for repeated measures with Tukey post-test; *p <0.05; ** p<0.01.  
 
3.8. Effects of heme on IL-8 production by IL-27 and IL-37 pre-stimulated 
neutrophils and monocytes 
Following 4 hours of pre-stimulation of neutrophil cultures with IL-27, heme was 
added to cultures over 18 hours. There was significant reduction of IL-8 secretion in 
neutrophil cultures compared to heme-stimulated neutrophils (Figure 6A). Similar 
reduction of IL-8 production was observed with IL-37 pre-stimulated neutrophils.  
In monocyte cultures, Figure 6B, IL-37 pre-stimulation inhibited the production of 
IL-8 by heme. IL-27 pre-stimulation yielded similar pattern in monocyte cultures. 
 
Figure 6: Effect of heme on IL-8 production by IL-27 and IL-37 pre-stimulated 
neutrophils (A) and monocytes (B) from control individuals (n=5).  US-unstimulated/ 
culture medium; HEME (30µM); IL-27 (5ng/mL); IL-37 (5ng/mL). One-way ANOVA for 
repeated measures with Tukey post-test; *p<0.05; **p<0.01;***p<0.001.  
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4. Discussion 
 Interleukin-37 and IL-27 are two (2) recently characterized cytokines with anti-
inflammatory activity. As far as we know, the role of both cytokines is yet to be studied 
in SCA or other hemolytic anemias. Therefore, for the first time, we give a report that 
serum IL-27 and IL-37 are elevated in SCA patients especially those who are 
hydroxyurea-naive compared to HbAA controls. This is consistent with previous studies 
in which IL-37 and IL-27 were elevated in patients with various chronic inflammatory 
diseases such as ankylosing spondylitis, rheumatoid arthritis, colitis and atherosclerosis 
(25, 29, 40-42). The findings from this study show that the studied anti-inflammatory 
cytokines as well as the pro-inflammatory cytokines were markedly produced in SCA 
patients. Elevated white cell count, neutrophils, lymphocytes, monocytes and platelets in 
both groups of SCA patients may have partly contributed to the elevated circulating levels 
of IL-27 and IL-37 as well as the pro-inflammatory cytokines. This is corroborated by 
other researchers who reported that leukocytes including neutrophils, 
monocytes/macrophages are important sources of cytokines in addition to other cell 
types (5, 8).   
 Serum IL-27 and IL-37 were weakly and positively correlated with pro-
inflammatory cytokines (IL-1β, IL-6, IL-8 and TNF-α; results not shown), which other 
researchers have described to be important in the pathogenesis of SCA (4, 11, 13, 18).  
Yang et al. found a positive association between serum IL-37 and pro-inflammatory 
cytokines; and Lai et al. found that elevated serum IL-27 were positively correlated with 
disease severity in patients with rheumatoid arthritis (42, 43). However, there was no 
positive correlation between IL-27 or IL-37 and the clinical complications in our patients. 
The different etiologies in these disease entities may be accountable for the disparity. 
While SCA is purely an inherited monogenic disorder in etiology, rheumatoid arthritis 
have an autoimmune component (43, 44). Contrary to other researchers, who found 
significant reduction in the levels of TNF-α and IL-1β in HU-treated patients compared to 
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the HU-naive patients, the use of HU was not associated with significant alteration in the 
levels of both pro- and anti-inflammatory cytokines in our cohort (15). Difference in the 
dose of HU, the duration of use of HU or some other modulators of the disease may 
explain this discordance. Hydroxyurea, the only approved hypomethylating agent, has 
previously been suggested to suppress inflammation (45, 46). The anti-inflammatory 
effect of HU could be supported by lack of significant difference in the serum level of all 
the pro-inflammatory cytokines (except IL-8) between the HU-treated SCA and the 
control group. It would be reasonable to suggest that HU helps to maintain the 
inflammatory milieu at a state that is similar to the baseline whereas inflammation is 
significantly augmented in the absence of HU. The anti-inflammatory cytokines in a 
similar way was not significantly different in the HU-treated patients compared to the 
controls. The pattern observed between HU-treated patients and HbAA controls could 
be corroborated by the weak positive correlation between the pro- and anti-inflammatory 
cytokine (results not shown).  
 A positive correlation between serum IL-27 and IL-37 in the SCA patients may 
suggest that the production of both cytokines may be induced by similar damage-
associated molecular pattern (DAMP), a group of endogenous molecules derived from 
damaged cells and extracellular matrix degradation capable of promoting and 
exacerbating immune responses (27). DAMPs such as free hemoglobin, heme or other 
breakdown products of RBC may have a role to play in the production of both groups of 
cytokines. Studies have shown that plasma levels of heme ranges from 20-600μM in 
patients with intravascular hemolysis such as SCA and paroxysmal nocturnal 
hemoglobinuria (PNH) (27, 47). Therefore, the effect noted in this study at a heme 
concentration of 30μM could be considered pathological. This effect may be extended to 
other conditions with raised heme levels for example cardiopulmonary bypass, hemolytic 
blood transfusion reactions (48, 49). Continuous hemolysis as is seen in patients with 
hemolytic anemias, of which SCA is an example, is associated with elevated IL-8 levels 
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as seen in both groups of SCA patients. In vitro experiments in the present study showed 
that heme stimulates pro-inflammatory response as evidenced by increased production 
of IL-8 in both neutrophil and monocyte cultures. The effect on other pro-inflammatory 
cytokines, IL-1β, IL-6 and TNF-α did not reach statistical significance (data not shown). 
Elevated heme levels overwhelm hemopexin, a potent heme scavenger; heme 
oxygenase; and stimulate the circulating monocytes and neutrophils, which secret IL-8 
(5, 44). In addition, the neutrophils produce IL-8, which self-activate in an autocrine 
fashion. Secreted IL-8 is responsible for neutrophilic chemoattraction to sites of 
endothelial injury as the neutrophils represent the most abundant innate immune cells. 
IL-8 may be important in SCA pathophysiology as earlier reported by Gonçalves et al. 
who suggested same as a maker of VOC in SCA patients (14). Clinical effects of IL-27, 
IL-37 or their antagonists on monocytes/macrophages and neutrophils as 
immunotherapy in patients with sickle cell disease and/ or hemolytic anemias may give 
desired results by ameliorating disease complications mediated by inflammation.  These 
agents may affect other cells in vivo such as T, B, NK cells, dendritic cells and 
macrophages , which express the IL-27R and IL-18R complexes if used in vivo (50, 51). 
Hence, the possible side effects that may emanate from the use of these agents or their 
targets/antagonists may be predictable.   
 The anti-inflammatory role of both IL-27 and IL-37 was further strengthened by 
inhibition of inflammatory response induced by heme in culture pre-stimulated with the 
IL-27 or IL-37. From the foregoing therefore, the use of IL-27 or IL-37 before sudden rise 
of heme concentration in hemolytic anemia could be protective and may ameliorate 
clinical complications mediated by innate immune response. This may be beneficial in 
acute episodes as well as chronic end organ morbidities. However, the inhibitory 
response of IL-27 and IL-37 was not obvious when these cytokines were added to heme 
pre-stimulated neutrophils and monocytes. This suggests that the presence of heme 
induces inflammatory pathways that could not be reversed or inhibited by the addition of 
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either IL-27 or IL-37. It could be inferred that the chronic inflammatory state induced by 
heme may play a positive feedback in inducing secretion of the pro-inflammatory 
cytokines and a negative feedback in inducing secretion of IL-37 and IL-27 (27, 29). 
Elevated levels of IL-37 and IL-27 maybe potent enough to regulate the excessive effect 
caused by the pro-inflammatory cytokines in a tendency to maintain the homeostatic 
balance thus, prevent excessive tissue damage. However, their potential inhibitory effect 
may not be sufficient to neutralize the effect of heme, as the latter is an inciting DAMP 
that initiated the inflammation cascade in these patients. Therefore, the probable use of 
IL-27 or IL-37 before sudden rise in circulating heme level may be preventive rather than 
therapeutic.  
 
5. Conclusions 
 Our results show that IL-27 and IL-37 levels are positively correlated in SCA 
patients and serum IL-27 and IL-37 are elevated in HU-naive patients compared to the 
controls. Furthermore, the use of HU did not significantly alter the secretion of both anti- 
and pro-inflammatory cytokines (except IL-8) in the HU-treated SCA patients compared 
to controls. This support the anti-inflammatory action of HU. In in vitro studies, heme at 
a concentration similar to pathological levels seen in hemolytic anemias such as SCA is 
a potent stimulus of IL-8 in neutrophils and monocytes. The marked upregulation of the 
pro-inflammatory pathway(s) leading to secretion of IL-8 in neutrophils and monocytes 
could be significantly suppressed by the use of IL-27 or IL-37 before sudden rise in the 
concentration of heme. IL-27 and IL-37 may play a regulatory role on the pro-
inflammatory pathways, as suggested by the in vitro studies. This role is probably 
sufficient to prevent further cellular or tissue damage but not potent enough to prevent 
inflammation. These cytokines may be immunotherapeutic targets in such scenarios.  
However, these findings should be interpreted with caution, as there are many 
modulating factors in SCA patients. 
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Limitation of the study: Children were not enrolled as participants. The findings would 
be more representative because children have less end organ damage due to chronic 
hemolysis and inflammatory response compared to adults.  
Highlights: 
 
 This study represent the first report on the role of IL-27 and IL-37 in sickle cell 
Anemia.    
 The   level   of   these   anti-inflammatory   cytokines   are   elevated   in 
hydroxyurea-naïve   SCA   patients   and   are   positively   correlated   with   
pro-inflammatory cytokines.  
 The level of these cytokines in the circulation may not be  sufficient  to   
neutralize   the   effects   of   pro-inflammatory   cytokines   in   SCA patients.  
 These   anti-inflammatory   cytokines   may   be   potential immunotherapeutic 
target for ameliorating complications in SCA patient  
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4. DISCUSSION 
 Interleukin-37 and Interleukin-27 are two (2) recently characterized 
cytokines with anti-inflammatory activity. From literature search, the role of both 
cytokines is yet to be studied in sickle cell anemia or other hemolytic anemias. 
Hence, for the first time, we give a report that serum IL-27 and IL-37 are elevated 
in SCA patients especially those who are hydroxyurea-naive compared with 
HbAA controls. This is consistent with previous studies in which IL-37 and IL-27 
were elevated in various chronic inflammatory diseases such as ankylosing 
spondylitis, rheumatoid arthritis, colitis, atherosclerosis (53, 57, 70-72). The 
findings from the present study show that IL-27 and IL-37 as well as the pro-
inflammatory cytokines were markedly produced in HU-naïve SCA patients.   
Elevated white cell count, neutrophils, lymphocytes, monocytes and platelets in 
both groups of SCA patients may have partly contributed to the elevated 
circulating levels of IL-27 and IL-37 as well as the pro-inflammatory cytokines. 
This is buttressed by other researchers who reported that leukocytes including 
neutrophils, monocytes/macrophages are important sources of cytokines in 
addition to other cell types (19, 34). Rudloff et al. observed that constitutive IL-37 
secretion by dendritic cells might serve to maintain an anti-inflammatory milieu at 
steady state, whereas IL-37 is stored in monocytes/macrophages to be available 
for rapid release upon inflammatory encounters thus, acting as a novel anti-
inflammatory alarmin (73). Similarly, macrophages and dendritic cells are the 
primary sources of IL-27 (58). These may partly explain the strong positive 
correlation between the serum IL-37 and IL-27 noted in our patients. More so, the 
secretion of both cytokines require the activation of Toll-Like Receptors (TLR) by 
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various pro-inflammatory stimuli, such as IL-1β, IL-18, TNF, IFN-gamma, or TLR 
agonists. 
 Serum IL-27 and IL-37 levels were positively correlated with pro-
inflammatory cytokines (IL-1β, IL-6, IL-8 and TNF-α; appendix 2, figure 3-6) in 
both HU-naïve and HU-treated patients. Most of these cytokines have been 
described to be important in the pathogenesis of SCA (37,39, 44,74).  Indeed, 
there is an association between the serum IL-27 or IL-37 levels and serum levels 
of pro-inflammatory cytokines; and between these cytokines and severity of the 
disease. Yang et al. reported a positive association between serum IL-37 and 
pro-inflammatory cytokines; and Lai et al. found that elevated serum IL-27 were 
positively correlated with disease severity in patients with rheumatoid arthritis (70-
72, 75). Zhao et al. found that the plasma level of IL-37 was positively correlated 
with pro-inflammatory cytokines (IL-17A, TNF-α) and disease activity in 
rheumatoid arthritis patients (56). The anti-inhibitory role of IL-37 could be 
explained by two hypothesis from existing studies:  either circulating IL-37 inhibits 
the actions of pro-inflammatory cytokines or their receptors, or IL-37 translocate 
to the nucleus where it interacts with SMAD3 pathway to interrupt transcription of 
pro-inflammatory cytokine genes (68, 76-78). A positive correlation between the 
pro- and anti-inflammatory cytokines suggests that these anti-inflammatory 
cytokines, IL-27 and IL-37 may have the role of reducing or limiting production 
and/or activities of the pro-inflammatory cytokine in SCA patients. However, there 
was no positive correlation between IL-27 or IL-37 and the clinical complications 
in the present study. The different etiologies in these disease entities may be 
accountable for the disparity. While sickle cell anemia is purely an inherited 
monogenic disorder in etiology, rheumatoid arthritis have an autoimmune 
60 
 
 
 
component (18, 75). Contrary to other researchers, who found significant 
reduction in the levels of TNF-α and IL-1β in HU-treated patients compared to the 
HU-naive patients, use of HU was not associated with a significant alteration in 
the levels of both pro and anti-inflammatory cytokines in the present studied (41). 
Difference in the dose of HU, the duration of use of HU or some other modulators 
of the disease may explain this discordance. Hydroxyurea, the only approved 
HbF-increasing drug has previously been suggested to suppress inflammation 
(79, 80). However, this study found that HU-treated patients had lower prevalence 
of leg ulcers thus, supporting previous report that include leg ulcers as an 
indication for use of HU (80). While most of our patients used a total dose of 
1000mg per day, a few were on 500mg or 1500mg per day (appendix 2, figure 1 
and 2). This finding suggests that the dose of HU required to give significant 
difference in each complication cannot be generalized rather may need to be 
individualized for each complication.  This could be exemplified by Saad et al., 
who observed that the use of hydroxyurea for prevention of priapism in SCD 
patients was successful. However, it was importantly pointed out that the dose 
required to stop priapism was higher than that normally used in their clinic for 
frequent painful crisis treatment, which is usually lower than 20 mg/kg (81). The 
anti-inflammatory effect of HU could be supported by lack of significant difference 
in the serum level of pro-inflammatory cytokines (except IL-8) between the HU-
treated SCA and the control groups. It would be reasonable to suggest that HU 
helps to maintain a balanced milieu at a state that is not significantly different 
from the baseline whereas in the absence of HU, inflammation is significantly 
enhanced. The anti-inflammatory cytokines in a similar way was not significantly 
different in the HU-treated patients compared to the controls. The pattern of the 
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two groups of cytokines observed between HU-treated patients and controls in 
the present study could be corroborated by positive correlation between the pro- 
and anti-inflammatory cytokine (appendix 2, figure 3-6).  
 There was a positive correlation between IL-27 and IL-37 in the 2 groups 
of SCA separately (appendix 2, figure 3A, 5A), hence both groups were analyzed 
together (figure 3). This indicates that HU may not significantly change the pattern  
or relationship between these 2 cytokines. A positive correlation between serum 
IL-27 and IL-37 in the SCA patients may suggest that the production of both 
cytokines may be induced by similar damage-associated molecular pattern 
(DAMP), a group of endogenous molecules derived from damaged cells and 
extracellular matrix degradation capable of promoting and exacerbating immune 
responses (55). DAMPs such as heme, free hemoglobin or other breakdown 
products of RBC may have a role to play in the production of both pro-
inflammatory and anti-inflammatory cytokines. Heme and other products of 
hemolysis are elevated in patients with SCA and other hemolytic anemias. 
Studies have shown that plasma levels of heme ranges from 20-600 μM in 
patients with intravascular hemolysis such as SCD and paroxysmal nocturnal 
hemoglobinuria (PNH) (82). Therefore, the effect noted in the in vitro experiments 
in this study at a heme concentration of 30 μM could be considered pathological. 
This effect may be extended to other conditions with raised heme levels for 
example cardiopulmonary bypass, hemolytic blood transfusion reactions (83, 84). 
  Heme has a pro-inflammatory property as consistently reported by other 
researchers (85). Continuous hemolysis seen in patients with hemolytic anemias 
is associated with elevated IL-8 levels similar to the observation in both  groups 
of SCA patients. In the in vitro experiments in the present study, it was shown 
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that heme stimulates pro-inflammatory response, evidenced by increased 
production of IL-8 in both human neutrophils and monocytes. The secretion of 
other quantified pro-inflammatory cytokines, IL-1β, IL-6 and TNF-α did not reach 
statistical significance (appendix 2, figure 7A-C and 8A-C). Though TNF-α and 
IL-1β were reported as important cytokines in the pathogenesis of SCD by some 
researchers who found elevated levels in SCD, some others did not find elevated 
levels in their cohort (41, 44). This supports the fact that elevated TNF-α level 
may be consistent with the acute pain crisis rather than the use of HU when 
compared with the steady state. Moreover, pre-stimulation of either neutrophils 
or monocytes with heme or rhIL-37 or rhIL-27 did not alter the concentration of 
these cytokines. Probably, heme alone may not be sufficient to enhance the 
secretion of this cytokines or that the threshold concentration necessary to 
significantly alter their secretion in neutrophils or monocytes was not reached. 
Elevated heme levels in hemolytic anemia and related conditions overwhelm 
hemopexin, a potent heme scavenger. This would subsequently overwhelm 
intracellular heme oxygenase and stimulate the upregulation of IL-8. 
Furthermore, excess heme stimulate monocytes to secret IL-8 with the major 
function of chemotaxis (18, 19). In addition, neutrophils produce IL-8, which help 
to stimulate self and other neutrophils in an autocrine and paracrine fashion 
respectively, hence contributing to acute inflammation. Interleukin-8 is 
responsible for neutrophilic chemoattraction to sites of endothelial injury. 
Neutrophils represent the most abundant innate immune cells and thereby play 
critical role in acute response of inflammation. IL-8 may play an important role in 
sickle cell anemia pathophysiology as earlier reported by Gonçalves et al. who 
suggested same as a maker of vaso-occlusion in SCA patients (40).   
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 The anti-inflammatory role of both IL-27 and IL-37 was further 
strengthened by inhibition of inflammatory response induced by heme in cultures 
pre-stimulated with the rhIL-27 or rhIL-37. It is interesting to emphasize that the 
concentration of rhIL-27 and rhIL-37 added to the cultures were very high (in 
nanograms) compared to the median concentrations of both cytokines (in 
picograms) found in the SCA patients. This suggests that the circulating levels in 
these patients are lower than the concentration that may be sufficient to reduce 
or nullify the inflammatory effect of heme thus, emphasizing a probable role  for 
these anti-inflammatory cytokines as immunotherapies in mitigating 
complications associated with SCA. From the foregoing therefore, the use of IL-
27 or IL-37 before sudden rise of a heme concentration in hemolytic anemia could 
be protective and may ameliorate clinical complications mediated by innate 
immune response. This may be beneficial in acute episodes as well as chronic 
end organ morbidities. However, the inhibitory response of IL-27 and IL-37 was 
not obvious when these cytokines were added to heme pre-stimulated 
neutrophils and monocytes. This suggests that the presence of heme induces 
inflammatory pathways that could not be reversed or inhibited by the addition of 
either IL-27 or IL-37. Putting this together, it could be inferred that the chronic 
inflammatory state induced by heme  and other products of hemolysis in patients 
with SCA and other hemolytic anemias may play a positive feedback in inducing 
secretion of the IL-8, a pro-inflammatory chemokine, which addition of IL-27 or 
IL-37 could not reverse (55, 57). Elevated levels of IL-37 and IL-27 maybe potent 
enough to regulate the excessive effect caused by the pro-inflammatory 
cytokines in a tendency to maintain the homeostatic balance and so prevent 
excessive tissue damage. However, their potential inhibitory effect at the 
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circulating concentration may not be sufficient to neutralize the effect of heme, as 
the latter is an inciting DAMP that initiated the inflammation cascade in these 
patients. Therefore, the probable use of IL-27 or IL-37 at a high concentration 
before sudden rise in circulating heme level may be preventive rather than 
therapeutic.  
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5. CONCLUSIONS 
 Our results show that IL-27 and IL-37 levels are positively correlated in 
SCA patients and serum IL-27 and IL-37 are elevated in HU-naive patients 
compared to the controls. Furthermore, the use of HU did not significantly alter 
the secretion of the both anti- and pro-inflammatory cytokines except IL-8 in the 
HU-treated SCA patients compared to controls thus, supports the anti-
inflammatory action of HU. In in vitro studies, heme at a concentration similar to 
pathological levels seen in hemolytic anemias such as SCA is a potent stimulus 
of IL-8 in neutrophils and monocytes. The marked up regulation of the pro-
inflammatory pathway(s) leading to secretion of IL-8 in neutrophils and 
monocytes could be significantly suppressed by the use of IL-27 or IL-37 before 
sudden rise in the concentration of heme. IL-27 and IL-37 may play a regulatory 
role on the pro-inflammatory pathways, as suggested by the in vitro studies. This 
role is probably sufficient to prevent further cellular or tissue damage but not 
potent enough to prevent inflammation. These cytokines may be 
immunotherapeutic targets in such scenarios.   
 
Limitation of the study: The study is a cross-sectional study hence caution must 
be taken in interpreting the results. In addition, because of the numerous 
modulators of SCA, there is need to carry out similar study in other group of 
patients with a different ethnic / genetic and environmental characteristics; 
preferably as a prospective study. 
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7. APPENDIX 
Appendix 1: Materials and Methods 
Figure 1. Flow chart for in vitro assay 
 
PBMC Peripheral blood mononuclear cells. 
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Appendix 2: Results 
Figure 2A: The duration of treatment with hydroxyrea in the hydroxyrea-
treated SCA patients.  Of the 47 HbSS patients on hydroxyurea, a majority 83% 
(39) had been on Hu for more than 12 months, 11% (5) for 3-6 months. 
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Figure 2B: The dose of hydroxyrea used by the Hydroxyurea-treated SCA 
patients.  Of the 47 HbSS patients on hydroxyurea, a majority 74% (35) had been 
regular on oral 1000g of HU, daily and 22% (10) were on 500g of HU daily. 
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Figure 3: Correlation of serum IL-37 with IL-27, IL-1β, IL-6, IL-8, TNF-α and 
TGF-β in the HbSS patients.  n=35; Spearman correlation for non-parametric 
data. 
Serum IL-37 and IL-27 were strongly and positively correlated, p<0.0001 and 
r=0.831among the 35 hydroxyurea-naïve SCA patients (figure A). Serum IL-37 
level was positively correlated with TNF-α level, IL-1β, IL-6 and IL-8 (p = 0.0004, 
p < 0.0001, p = 0.0007, p = 0.0001 respectively; figure B-E). However, the 
correlation of IL-37 with TGF- β was not significant (p=0.412; figure F) 
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Figure 4: Correlation of serum IL-27 with IL-1β, IL-6, IL-8, TNF-α and TGF-β 
in the HbSS patients. n=35; Spearman correlation for non-parametric data. 
Serum IL-27 level was positively correlated with TNF-α level, IL-1β, IL-6 and IL-
8 (p = 0.017, p <0.002, p = 0.013, p =0.001 respectively; figure A-D). However, 
the correlation of IL-27 with TGF- β was not statistically significant (p=0.575; 
figure E). 
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Figure 5: Correlation of serum IL-37 with IL-27, IL-1β, IL-6, IL-8, TNF-α and 
TGF-β in the HbSSHU patients. n=42; Spearman correlation for non-parametric 
data. 
Similar to the hydroxyurea-nafor non-parametric data. IL-8, TNF-GF-β in the 
HbSS patientsients;5(115).5).md IL-27 among the hydroxyurea-treated SCA 
patients, p<0.0001 and r = 0.872 (figure A). TNF-α, IL-1β, IL-6 and IL-8, were 
positively correlated with IL-37 (p<0.0001, p=0.002, p=0.0003 and p=0.0009 
respectively; figure B-E). 
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Figure 6: Correlation of serum IL-27 with IL-1β, IL-6, IL-8, TNF-α and TGF-β 
in the HbSS patients. n=42; Spearman correlation for non-parametric data. 
When IL-27 was correlated with TNF-α, IL-1β, IL-6 and IL-8 in the hydroxyurea-
treated sickle cell anemia patients, there was a significant positive correlation 
between IL-27 and TNF-α (p<0.017, figure A). Correlation of IL-27 and IL-1β, 
IL-6 and IL-8, was positive (p=0.002, p<0.013 and p=0.001 respectively; figure B-
D).  
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Figure 7. Effect of IL-27 and IL-37 on heme- induced production of pro-
inflammatory cytokine in neutrophils (n=5). 
In neutrophil cultures, 4 hours pre-stimulation with rhIL-27 or rhIL-37 before heme 
was added, yielded a significantly higher secretion of TNF-α compared with 
incubation with heme alone, p= < 0.01 in each case (figure A). There was no 
significant difference in the secretion of IL-1β and IL-6 (figure B and C). 
HEME/IL27, 4-hour pre-stimulation before addition of rhIL-27; HEME/IL37, 4-hour 
pre-stimulation with heme before addition of rhIL-37; IL27/HEME, 4-hour pre-
stimulation with rhIL27 before addition of heme; IL37/HEME, 4-hour pre-
stimulation with rhIL37 before addition of heme; TNF/HEME, 4-hour pre-
stimulation with rhTNF-α before addition of heme.*p < 0.05, **p < 0.01, ***p < 
0.001. 
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Figure 8. Effect of IL-27 and IL-37 on heme- induced production of pro-
inflammatory cytokine in monocytes (n=5). 
In monocyte cultures, 4 hours pre-stimulation with rhIL-27 before heme was 
added, yielded a significantly higher secretion of TNF-α compared with incubation 
with rhIL-37 alone, p = < 0.05 in each case (figure A). Pre-stimulation with heme 
before addition of rhIL-27 or rhIL-37 and pre-stimulation with cytokines before 
addition of heme did not yield significant alteration in the concentration in TNF-α, 
IL-1β and  IL-6 (figure A, B and C).  HEME/IL27, 4-hour pre-stimulation before 
addition of rhIL-27; HEME/IL37, 4-hour pre-stimulation with heme before addition 
of rhIL-37; IL27/HEME, 4-hour pre-stimulation with rhIL27 before addition of 
heme; IL37/HEME, 4-hour pre-stimulation with rhIL37 before addition of heme; 
TNF/HEME, 4-hour pre-stimulation with rhTNF-α before addition of heme. .*p < 
0.05, **p < 0.01, ***p < 0.001. 
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Appendix 3: Ethical approvance 
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